Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins

被引：74

作者：

Bermudez-Humaran, Luis G. ^{[1
]}

机构：

[1] INRA 0910, Unite Ecol & Physiol Syst Digestif, Equipe Interact Bacteries Commensales & Probiot A, F-78352 Jouy En Josas, France

来源：

HUMAN VACCINES | 2009年 / 5卷 / 04期

关键词：

lactic acid bacteria; Lactococcus lactis; mucosal vaccines; cytokines; antigens; TOXIN FRAGMENT-C; INTRANASAL IMMUNIZATION; NASAL VACCINATION; IMMUNE-RESPONSES; TETANUS TOXIN; E7; ANTIGEN; RECOMBINANT; MICE; VACCINES; INTERLEUKIN-10;

D O I：

10.4161/hv.5.4.7553

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Food-grade lactic acid bacteria (LAB) have been safely consumed by humans for centuries in fermented foods. Lactococcus lactis, a LAB widely used in the dairy industry as a starter, can be genetically engineered to efficiently produce a large variety of proteins. This feature has been recently exploited by scientists for the development of a new generation of vectors to deliver therapeutic proteins to the mucosal tissues. The successful Phase I clinical trial with a L. lactis strain secreting interleukin-10 for Crohn's disease has opened new horizons for the use of genetically engineered LAB as delivery vehicles. This commentary reviews the current advances made with L. lactis as live vector for the mucosal delivery of therapeutic proteins.

引用

收藏

页码：264 / 267

页数：4

相关论文

共 40 条

[31] Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C [J].

Norton, PM ;

Wells, JM ;

Brown, HWG ;

Macpherson, AM ;

LePage, RWF .

VACCINE, 1997, 15 (6-7) :616-619

[32] Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis:: a first step towards food-grade live vaccines against brucellosis [J].

Ribeiro, LA ;

Azevedo, V ;

Le Loir, Y ;

Oliveira, SC ;

Dieye, Y ;

Piard, JC ;

Gruss, A ;

Langella, P .

APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2002, 68 (02) :910-916

[33] Oral vaccination of mice against tetanus with recombinant Lactococcus lactis [J].

Robinson, K ;

Chamberlain, LM ;

Schofield, KM ;

Wells, JM ;

LePage, RWF .

NATURE BIOTECHNOLOGY, 1997, 15 (07) :653-657

[34] Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity [J].

Shanley, JD ;

Wu, CA .

VACCINE, 2005, 23 (08) :996-1003

[35]

SINGH M, 2008, HUM VACCINES, V4, P44

[36] Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 [J].

Steidler, L ;

Neirynck, S ;

Huyghebaert, N ;

Snoeck, V ;

Vermeire, A ;

Goddeeris, B ;

Cox, E ;

Remon, JP ;

Remaut, E .

NATURE BIOTECHNOLOGY, 2003, 21 (07) :785-789

[37] Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 [J].

Steidler, L ;

Hans, W ;

Schotte, L ;

Neirynck, S ;

Obermeier, F ;

Falk, W ;

Fiers, W ;

Remaut, E .

SCIENCE, 2000, 289 (5483) :1352-1355

[38] Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria [J].

Wells, Jerry M. ;

Mercenier, Annick .

NATURE REVIEWS MICROBIOLOGY, 2008, 6 (05) :349-362

[39] LACTOCOCCUS-LACTIS - HIGH-LEVEL EXPRESSION OF TETANUS TOXIN FRAGMENT-C AND PROTECTION AGAINST LETHAL CHALLENGE [J].

WELLS, JM ;

WILSON, PW ;

NORTON, PM ;

GASSON, MJ ;

LEPAGE, RWF .

MOLECULAR MICROBIOLOGY, 1993, 8 (06) :1155-1162

[40] Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease [J].

Yuvaraj, Saravanan ;

Lahham, Saed ;

Marreddy, Ravi K. R. ;

Dijkstra, Gerard ;

Wolken, Wout A. M. ;

Lolkema, Juke S. ;

Helfrich, Wijnand ;

Johansen, Finn-Erik ;

Peppelenbosch, Maikel P. ;

Bos, Nicolaas A. .

MOLECULAR NUTRITION & FOOD RESEARCH, 2008, 52 (08) :913-920

← 1 2 3 4 →